KRAS and cancer: The combination of atypical BRAF and other atypical Ras mutations (in KRAS, NRAS, or NF1) is consistent with a “mini-driver” model in which some cancers acquire sufficient Ras activation through a two-step process rather than a single “hit” at BRAFV600E or one of the common KRAS hotspots.